AIRLINK 62.48 Increased By ▲ 2.05 (3.39%)
BOP 5.36 Increased By ▲ 0.01 (0.19%)
CNERGY 4.58 Decreased By ▼ -0.02 (-0.43%)
DFML 15.50 Increased By ▲ 0.66 (4.45%)
DGKC 66.40 Increased By ▲ 1.60 (2.47%)
FCCL 17.59 Increased By ▲ 0.73 (4.33%)
FFBL 27.70 Increased By ▲ 2.95 (11.92%)
FFL 9.27 Increased By ▲ 0.21 (2.32%)
GGL 10.06 Increased By ▲ 0.10 (1%)
HBL 105.70 Increased By ▲ 1.49 (1.43%)
HUBC 122.30 Increased By ▲ 4.78 (4.07%)
HUMNL 6.60 Increased By ▲ 0.06 (0.92%)
KEL 4.50 Decreased By ▼ -0.05 (-1.1%)
KOSM 4.48 Decreased By ▼ -0.09 (-1.97%)
MLCF 36.20 Increased By ▲ 0.79 (2.23%)
OGDC 122.92 Increased By ▲ 0.53 (0.43%)
PAEL 23.00 Increased By ▲ 1.09 (4.97%)
PIAA 29.34 Increased By ▲ 2.05 (7.51%)
PIBTL 5.80 Decreased By ▼ -0.14 (-2.36%)
PPL 107.50 Increased By ▲ 0.13 (0.12%)
PRL 27.25 Increased By ▲ 0.74 (2.79%)
PTC 18.07 Increased By ▲ 1.97 (12.24%)
SEARL 53.00 Decreased By ▼ -0.63 (-1.17%)
SNGP 63.21 Increased By ▲ 2.01 (3.28%)
SSGC 10.80 Increased By ▲ 0.05 (0.47%)
TELE 9.20 Increased By ▲ 0.71 (8.36%)
TPLP 11.44 Increased By ▲ 0.86 (8.13%)
TRG 70.86 Increased By ▲ 0.95 (1.36%)
UNITY 23.62 Increased By ▲ 0.11 (0.47%)
WTL 1.28 No Change ▼ 0.00 (0%)
BR100 6,941 Increased By 63.6 (0.92%)
BR30 22,802 Increased By 233 (1.03%)
KSE100 67,142 Increased By 594.3 (0.89%)
KSE30 22,090 Increased By 175.1 (0.8%)

The largest pharma firm in Pakistan, GlaxoSmithKline Pakistan Limited started the year off on a high note - top line growth was 7 percent year-on-year while costs were kept very low, shooting up gross profit by 16 percent. The bottom line gain was an impressive 35 percent over last year.

GSK's margins have improved significantly. This is likely to have been achieved through product portfolio rationalization, a better sales mix, and synergies achieved through consolidation of manufacturing operations in previous quarters. Moreover, the company has enjoyed price adjustments on a few older products in the past as well, and there was a fresh round of price increases on drugs in 2016 as well. A handful of multinationals obtained a stay order from the Sindh High Court on price increases for certain medicines, including GSK. This would have improved the company's top line as well as its margins.

In the recent past, GSK has been growing its exports as well. Although they account for little in comparison to the domestic market, the recent depreciation of the Rupee would have helped on this front.

table-4

The consumer healthcare segment earns its take from solid brands like Horlicks, Sensodyne and Panadol and has accounted for almost 20 percent of the firm's revenues. GSK is close to spinning off this segment into a separate listed company called GlaxoSmithKline Consumer Healthcare Pakistan Limited.

Comments

Comments are closed.